AstraZeneca prices four-tranche $3bn global bond offering
15th Aug 2018 08:56
(Sharecast News) - AstraZeneca priced a four-tranche global bond offering totalling $3bn on Tuesday, it announced on Wednesday morning.
Read moreSector movers: Miners, Big Oil and pharma lead gains
7th Aug 2018 18:16
(Sharecast News) - Commodity-related stocks paced gains on Tuesday following the release of figures overnight showing that China's foreign exchange reserves didn't jump last month.
Read moreAstraZeneca, Merck NF1 treatment granted orphan status by EMA
3rd Aug 2018 07:52
(Sharecast News) - AstraZeneca and Merck said the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1) an incurable genetic condition that affects one in 3,000 newborns worldwide.
Read moreAstraZeneca's lung cancer treatment gains positive opinion from CHMP
27th Jul 2018 14:53
(Sharecast News) - AstraZeneca on Friday received a marketing authorisation for its lung cancer treatment Imfinzi from the committee for medicinal products for human use (CHMP).
Read moreAstraZeneca offloads Atacand rights in $200m deal
24th Jul 2018 07:11
(Sharecast News) - AstraZeneca has agreed to sell the commercial rights to Atacand - candesartan cilexetil - and Atacand Plus - a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide - in Europe to Cheplapharm Arzneimittel, it announced on Tuesday.
Read moreFriday broker round-up
17th Feb 2017 09:19
(ShareCast News) - AstraZeneca: Jefferies reiterates Buy with a target price of 5250p. BT Group: Jefferies reiterates Hold with a target price of 325p. Standard Life: Macquarie reiterates Outperform with a target price of 450p. Cobham: Goldman Sachs reiterates Sell with a target price of 88p. Dra
Read moreAstraZeneca reports positive results from breast cancer drug trial
17th Feb 2017 07:08
(ShareCast News) - AstraZeneca on Friday reported positive results from its Phase III OLYMPIAD trial of its breast cancer treatment Lynparza (olaparib). Patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) c
Read moreLondon close: FTSE falls on dollar dip, ex-divs and tendency to gold safety
16th Feb 2017 17:00
(ShareCast News) - London equities limped to a lower close Thursday, pulled down by a trinity of factors including dollar weakness, a tendency to safe-haven gold and ex-dividend stocks. These combined to see the FTSE 100 down 0.34% to 7,277.92, and the FTSE 250 down -0.65%% to 18,705.72. Both ladder
Read moreAstraZeneca partner Valeant gets US FDA approval for Siliq injection
16th Feb 2017 14:42
(ShareCast News) - AstraZeneca's partner Valeant Pharmaceuticals has received approval from the US Food and Drug Administration for the Siliq injection to treat adult patients with moderate-to-severe plaque psoriasis. The pharmaceuticals giant has given Valeant the exclusive license to develop and c
Read moreAstrazeneca still a 'buy' after profit warning, says Deutsche Bank
6th Feb 2017 10:17
(ShareCast News) - Deutsche Bank has reiterated a 'buy' rating on Astrazeneca but cut the target price to 5,500p from 6,000p after the drug maker warned that profit and revenue would fall this year. Last Thursday Astrazeneca issued a profit warning as cheaper generic versions of its cholesterol drug
Read moreLondon open: FTSE gains ahead of BoE, Brexit White Paper
2nd Feb 2017 08:31
(ShareCast News) - London stocks were slightly higher in early trading on Super Thursday, as investors awaited a rate decision from the Bank of England, the Inflation Report and minutes together with the government's White Paper on Brexit. As of 0835 GMT the FTSE 100 was up 0.21% or 15.05 points at
Read moreAstraZeneca sales shrink but future hangs on drug pipeline
2nd Feb 2017 08:08
(ShareCast News) - AstraZeneca reported a second interim dividend after posting flat core earnings for 2016 after a 13% decline in revenues in the fourth quarter, but the company and investors are holding their breath in hope that 2017 will be "a defining year" for a dozen potential blockbuster drug
Read moreSector movers: Cyclicals bounce back, Evraz in the lead
1st Feb 2017 15:46
(ShareCast News) - There was a clear split in the market on Wednesday as cyclicals bounced back and the more defensive segments of the market were relegated to the bottom of the pile. Thus, shares in Prudential and Aviva were to be seen pacing gains among life insurers as yields on benchmark 10-year
Read moreMonday broker round-up
30th Jan 2017 13:05
(ShareCast News) - BT: Barclays reiterates overweight with a target price of 475p. ITV: Jefferies reiterates buy, 230p target. Phoenix: Deutsche Bank restarts coverage at buy with a 835p target. Paragon Group: JP Morgan reiterates underweight with a 355p target. Inmarsat: Deutsche Bank reiterates
Read moreFTSE 100 movers: Tesco gains while Sainsbury's loses out
27th Jan 2017 15:38
(ShareCast News) - The FTSE 100 index rose 0.17% to 7,173.75 in the late afternoon. Supermarket giant Tesco climbed as it announced it has agreed to merge with the UK's largest food wholesale operator Booker Group. Under the terms of the merger, each Booker scheme shareholder would receive 0.861 new
Read more